• Health
  • Science
  • U.S.
  • Technology
  • Business
  • World
  • Politics
  • Entertainment
  • Sports

Building a Better World

News and information

  • Home
  • Privacy Policy
  • Contact Us
  • Our Team

FDA vote is divided over approval of new blood clot preventing drug

February 17, 2014 By Contributor

FDA vote is divided over approval of new blood clot preventing drug

A new drug has divided the FDA.

Reviewers for the Food and Drug Administration are divided on whether or not to approve an intravenous blood clot preventive named cangrelor, developed by The Medicines Co.

In a report posted on Monday, Feb. 10, Medical Team Leader at the FDA’s Center for Drug Evaluation, Dr. Thomas Marciniak urged that cangrelor not be approved, explaining that there was not enough evidence to prove that the drug would be more effective than its current competitor, while DRs. Fred Senatore and Nhi Beasley suggested that the drug be approved, explaining that cangrelor could be beneficial in providing reduced risks for individuals undergoing Percutaneous Coronary Intervention, or PCI.

The drug is designed to prevent blood clots during certain medical procedures. Cangrelor was tested on a sample of more than 11,000 patients and results showed that patients taking cangrelor versus competitor brand Plavix, had a 22 percent lower risk of experiencing complications such as heart attack, repeat procedure, stent thrombosis, or death, 48 hours after surgery.

While the trial deemed itself successful over its competitor, these results came only after two previous trials of the drug which had both failed. Marcianak stressed the importance of The Medicines Co conducting another trial before the approving the drug, a view that not all reviewers supported.

The Medicines Co, which suffered a 7 percent decrease in stock on Monday, Feb. 10, after the report came out, would generate an estimated $226 million in sales by 2018, if cangrelor is approved, according to data produced by Thomson Reuters.

While Marcianak stands firm on his opinion that further trials must be initiated before approval of the drug can be made, other reviewers believe that the drug fulfilled the goals of the trial. The report, which came out on Monday, was published two days prior to a meeting which is to be held among experts outside of the FDA. Though the FDA is not required to vote based on the recommendation of its advisors, it historically has.

 

Sharing

Facebooktwittergoogle_plusredditpinterestlinkedintumblrmail

Filed Under: Front Page, Health, None

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

Follow Us

Facebookrss

Search:

Recent Posts

  • NASA’s InSight spacecraft makes important course correction May 26, 2018
  • Scientists outraged at latest Trump decision May 15, 2018
  • Huge uproar erupts over major incident at Utah park May 13, 2018
  • Incredible moon discovery stuns scientists May 12, 2018
  • Authorities shocked by discovery about common painkiller May 6, 2018
  • Outrageous crocodile experiment stuns scientists May 5, 2018
  • Great Barrier Reef is too quiet, scientists say May 1, 2018
  • Massive Hiroshima bomb discovery shocks scientists May 1, 2018
  • Earth will be slammed by massive asteroid April 29, 2018
  • Teens are doing something incredibly alarming in schools April 29, 2018
  • Huge discovery in Tasmania stuns scientists April 28, 2018
  • Shocking discovery in New Jersey stuns authorities April 22, 2018
  • Huge volcanic explosion could wipe out the United States April 21, 2018
  • Huge controversy erupts over world’s hottest pepper April 15, 2018
  • SpaceX is about to do something astonishing April 15, 2018

Copyright © 2021 Jones Kilmartin Group, LLC · Metro Pro Theme On Genesis Framework · WordPress